1. Pink Sheet
  2. >>Advanced Technologies
  3. >>Cell & Gene Therapies

Invossa Approval Revoked As Korea Confirms False Data Submission

 
• By Jung Won Shin

In a worst case scenario for the country’s first approved gene therapy, South Korea has cancelled the global-first approval of Kolon Life’s Invossa and asked prosecutors to press criminal charges against the company, which it concluded submitted false data to support approval. The major blow to the company comes as it is already facing lawsuits from patients and investors, and has prompted a broader regulatory overhaul for novel biologic therapies.

MFDS
Korean Regulators Announce Decision On Gene Therapy Invossa • Source: Korea Ministry of Food and Drug Safety

South Korea’s Ministry of Food and Drug Safety (MFDS) has canceled the approval of Kolon Life Science Inc.’s pioneering cell and gene therapy Invossa (TG-C), after it concluded the company submitted false data at the time of approval. The ministry has also asked prosecutors to press criminal charges against the company.

The move, effective 28 May, follows the MFDS’s probe and due diligence into Kolon Life’s US subsidiary Kolon TissueGene, which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cell & Gene Therapies

More from Advanced Technologies

UK’s Decentralized Manufacturing Rules Designed To Allow For ‘Future Developments’

 
• By Eliza Slawther

The UK drug regulator acknowledges that technology will “move on” and, as such, has designed its decentralized manufacturing regulation to be as “enduring” as possible. Experts from the MHRA explain what products are covered by the new framework and how it has been future-proofed.

Profit-Sharing AI Model Proposed To Boost Korean Drug R&D

 
• By Jung Won Shin

A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges

US FDA’s Top Cell and Gene Therapy Regulators Forced Out

 
• By Sarah Karlin-Smith

Office of Therapeutic Products Director Nicole Verdun and her deputy Rachael Anatol were escorted out of FDA headquarters on June 18. Disagreements over CAR-T regulation and Capricor’s DMD treatment may be to blame.